Sales Performance - Immuron Limited has achieved record sales exceeding AUD$5 million in a fiscal year, marking the highest sales in the company's history [1][2] - For the March 2025 quarter, global sales reached AUD$1.3 million, a 2% increase compared to the prior year, while year-to-date sales amounted to AUD$5.3 million, reflecting a 46% increase [1][2] - In Australia, year-to-date sales were AUD$3.7 million, up 34% year-over-year, with the March 2025 quarter sales at AUD$0.5 million, a 28% increase [1][2] - North American sales for the year-to-date reached AUD$1.6 million, an impressive 86% increase compared to the previous year [1][2] Product Overview - Travelan® is an over-the-counter immune supplement designed to target pathogenic bacteria and their toxins in the gastrointestinal tract, reducing the likelihood of travelers' diarrhea [1][4] - The product is available in Australia as a listed medicine, in Canada as a licensed natural health product, and in the U.S. as a dietary supplement [4] Market Position - Travelan® has been ranked 1 by market share change, 2 by SKU, and 3 by brand in the Anti-diarrheal category in Australia [2] - The company has seen strong sales growth due to its travel activation program and expanded pharmacy agreements, particularly in the lead-up to peak travel seasons [2]
Immuron Travelan® highest sales in history